Home

Calls for the strengthening of national and multilateral approaches and international co- operation, such as the COVAX Facility created within the ACT-A, and other relevant initiatives as appropriate, in order to facilitate equitable and affordable access to COVID-19 vaccines in armed conflict situations, post-conflict situations and complex humanitarian emergencies, stresses the need to develop international partnerships particularly to scale-up manufacturing and distribution capabili- ties, in recognition of differing national contexts, and notes the need to maintain incentives for the de- velopment of new health products; and recognising the role of extensive immunisation against COVID-19 as a global public good for health; 2. (...) Calls for full, safe, and unhindered humanitarian access, without delay, for humanitarian personnel and medical personnel, their equipment, transport and supplies, in order to facilitate, inter alia, COVID-19 vaccinations, as appropriate, and calls for the protection, safety, and security of such humanitarian and medical personnel, and in this regard urges all parties to protect civilian infrastruc- ture which is critical to the delivery of humanitarian aid for essential services concerning vaccinations and related medical care, in situations of armed conflicts and complex humanitarian emergencies; 5. (...) Demands that all parties to armed conflicts fully comply with their obligations under in- ternational law, including international human rights law, as applicable, and international humanitar- ian law, in particular their obligations under the Geneva Conventions of 1949 and the obligations, as applicable, under the Additional Protocols of 1977 and 2005, to ensure the respect and protection of all medical personnel and humanitarian personnel exclusively engaged in medical duties, their means of transport and equipment, as well as hospitals and other medical facilities; 7.

REPORT OF THE SPECIAL RAPPORTEUR ON THE ADVERSE EFFECTS OF THE ILLICIT MOVEMENT AND DUMPING OF TOXIC AND DANGEROUS PRODUCTS AND WASTES ON THE ENJOYMENT OF HUMAN RIGHTS, CALIN GEORGESCU : ADDENDUM

Examples are: foodstuffs, water samples, living persons and substances which have been treated so that the pathogens have been neutralized or deactivated. 2.6.3.2.6 A live animal which has been intentionally infected and is known or suspected to contain an infectious substance shall only be transported under terms and conditions approved by the competent authority. 2.6.3.3 Biological products 2.6.3.3.1 For the purposes of these Regulations, biological products are divided into the following groups: (a) those which are manufactured and packaged in accordance with the requirements of appropriate national authorities and transported for the purposes of final packaging or distribution, and use for personal health care by medical professionals or individuals. (...) Medical or clinical wastes containing infectious substances in Category B, other than cultures, shall be assigned to UN 3291. 2.6.3.5.2 Medical or clinical wastes which are reasonably believed to have a low probability of containing infectious substances shall be assigned to UN 3291. NOTE: The proper shipping name for UN 3291 is "CLINICAL WASTE, UNSPECIFIED, N.O.S." or "(BIO) MEDICAL WASTE, N.O.S" or "REGULATED MEDICAL WASTE, N.O.S.". 2.6.3.5.3 Decontaminated medical or clinical wastes which previously contained in

They are used in processes for food and beverage packaging, piping, medical product manufacturing and recycling. Melt pressure products entered the market in the 1950s, initially protected by a patent, which influenced their supply and market prices. (...) Currently, melt pressure products are not covered by the Minamata Convention. (...) In addition, the majority of manufacturers also produce melt pressure transducers which use silicon oil as an alternative transmission medium. Although these products have limits on the temperature which they can withstand, their use is ideal in food, medical and pharmaceutical applications.

Social Development Cooperation 4.1 Development Cooperation 4.2 Medical Care and Public Health 4.3 Education and Human Resources 4.4 Sharing of Poverty Reduction Experience 4.5 Science and Technology Cooperation and Knowledge Sharing 4.6 Environmental Protection and Tackling Climate Change 5. (...) China will explore possibilities to facilitate trade of sugar products with high potentials. 3.1.11 Both sides will work together in the agro-industrial sector to increase the capacity of agri-entrepreneurs to export their products on the regional market and enhance skills of farmers at grass root level in modern farm management techniques. (...) The two sides will roll out visa facilitation policies as appropriate and streamline customs procedures to enable easier traveling so that mutual tourist visits could steadily increase. 3.6.2 The two sides will continue to invite one another to attend tourism exhibitions and hold promotion events to build platforms for experience sharing, business negotiations and products promotion for Chinese and African government agencies and tourism businesses.

REPORT OF THE SPECIAL RAPPORTEUR ON THE ADVERSE EFFECTS OF THE MOVEMENT AND DUMPING OF TOXIC AND DANGEROUS PRODUCTS AND WASTES ON THE ENJOYMENT OF HUMAN RIGHTS, OKECHUKWU IBEANU : ADDENDUM

The competent authorities should impose any conditions they deem appropriate to prevent the equipment and products being used for the purpose of capital punishment or for the purpose of torture and other cruel, inhuman or degrading treatment or punishment. (...) (7) It is therefore appropriate to lay down Community rules on trade with third countries in equipment and products which could be used for the purpose of capital punishment and in equipment and products which could be used for the purpose of torture and other cruel, inhuman or degrading treatment or punishment. (...) E/CN.4/2003/69 Page 22 � against escape during a transfer, on medical grounds as directed by a medical officer, or, if other methods of control fail, in order to prevent a prisoner from injuring himself or others, or from damaging property

BWC/MSP/2009/MX/INF.1 Page 14 products; and exploring promoting possible incentive schemes for research and development on diseases that disproportionately affect the developing world (...) • Improving delivery and access to all health products and medical devices by effectively overcoming barriers to access through: encouraging increased investment in health- delivery infrastructure and encourage financing of health products in order to strengthen the health system; establishing and strengthening mechanisms to improve ethical review and regulate the quality, safety, and efficacy of health products and medical devices; and promoting competition to improve availability and affordability of health products consistent with public health policies and needs (...) • Securing and enhancing sustainable financing mechanisms for research and development and developing and delivering health products and medical devices to address the health needs of developing countries is to be accomplished by: and endeavouring to secure adequate and sustainable financing for research and development and improve coordination of its use; making maximum use of current initiatives and complementing them as appropriate

In the field of macroeconomic policies, guidelines 23 to 25 of the Guidelines of the Economic and Social Policy of the Party for 2016 to 2021 indicate the objectives of increasing gross domestic product (GDP); ensuring a level of sustainable development to reach higher levels of productivity in all sectors of the economy, science, technology and innovation; ensuring a progressive decrease in the subsidies provided by the State; and contributing to improve, as much as possible, the offer of products and services to the population. (...) Polyclinics, in which patients receive primary medical attention and care, are the entry points to the health-care system for the population. (...) Cuba also provided assistance to children who were brought to Cuba for medical treatment after the Chernobyl nuclear accident, which took place in 1986.

We reject the idea of inhibiting the application of biological processes in the development of materials and substances for industrial, medical and pharmaceutical uses alleging possible "harmful use" of technology to produce weapons. (...) United States Possession, Use, and Transfer of Select Agents and Toxins The Law Public Health Security and Bioterrorism Preparedness and Response Act of 2002 – Signed by President Bush on June 12, 2002 • Secretary of Heath and Human Services • Secretary of Agriculture • Attorney General of the United States HHS and USDA • Establish a list of biological agents and toxins that have the potential to pose a severe threat to: – HHS: public health and safety – USDA: animal and plant health, or to animal and plant products • Identification and registra